Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biodesix (BDSX)
NASDAQ:BDSX
Holding BDSX?
Track your performance easily
Earnings Data
Report Date
Mar 18, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.07Last Year’s EPS
-$0.1Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2024
|% Change Since: -7.65%
|Next Earnings Date:Mar 18, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights Biodesix's strong revenue growth and high gross margins, driven by success in lung diagnostic testing and an increase in biopharma services contracts. However, challenges such as the impact of hurricanes on sales, a decline in biopharma services revenue, and increased operating expenses were noted. The company remains confident in achieving its full-year revenue guidance and future profitability.Company Guidance
During the third quarter 2024 earnings call for Biodesix, the company provided guidance emphasizing strong financial performance and strategic priorities. They reported a 35% year-over-year increase in revenue, reaching $18.2 million, with lung diagnostic testing revenue witnessing a 40% growth, driven by a 34% increase in test volumes. The company's gross margins were reported at 77%, and they achieved a 6% improvement in net loss. Despite challenges such as hurricanes in the Southeast affecting operations, Biodesix reiterated their full-year 2024 revenue guidance of $70 million to $72 million. They also expect to achieve adjusted EBITDA breakeven in the second half of 2025. The company aims to further expand its sales team and continue driving the adoption of their lung diagnostic tests and biopharma services.Strong Year-over-Year Revenue Growth
Biodesix reported a 35% year-over-year growth in revenue for Q3 2024, with total revenue reaching $18.2 million.
Lung Diagnostic Testing Success
Lung diagnostic testing revenue grew by 40% year-over-year, driven by a 34% increase in test volumes and new coverage policies.
High Gross Margin
The company maintained a high gross margin of 77% in Q3 2024, slightly up from 76.1% in the prior year quarter.
Record Biopharma Services Contracted Revenue
Biopharma services saw an increase in dollars under contract, reaching a record high of $11.1 million, up from $8.1 million in Q2 2024.
Reaffirmation of 2024 Guidance
Biodesix reaffirmed its 2024 full-year revenue guidance of $70 million to $72 million and expects adjusted EBITDA breakeven in the second half of 2025.
---
BDSX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BDSX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 01, 2024 | $1.70 | $1.30 | -23.53% |
| Aug 07, 2024 | $1.59 | $1.64 | +3.14% |
| May 08, 2024 | $1.55 | $1.55 | 0.00% |
| Mar 01, 2024 | $1.54 | $1.58 | +2.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biodesix (BDSX) report earnings?
Biodesix (BDSX) is schdueled to report earning on Mar 18, 2025, TBA Not Confirmed.
What is Biodesix (BDSX) earnings time?
Biodesix (BDSX) earnings time is at Mar 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BDSX EPS forecast?
BDSX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.07.
---